The global targeted data center market size was estimated at USD 232.32 billion in 2025 and is predicted to increase from USD 255.41 billion in 2026 to approximately USD 599.3 billion by 2035, expanding at a CAGR of 9.94% from 2026 to 2035. The market growth is fueled by the rise in R&D activities, the adoption of advanced technologies, expanding collaborations, and growing investments.
Contract pharmaceutical manufacturing is the business agreement between the pharmaceutical companies and specialized third-party organizations commonly known as contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). These organizations help in the manufacturing of various drug products by offering production, formulation, quality control, and packaging services. Key drivers include rising demand for affordable services, shorter drug development timelines, specialized expertise, generic products, increasing innovations, and expanding technological advancements.
By service type, the contract manufacturing (CMO) segment held the dominating share of approximately 65% in the market in 2025, as it offered affordable services as well as specialized expertise. The growth in the demand for finished products and a focus on R&D and innovation also attracted the consumers. Moreover, their faster drug commercialization and regulatory support also increased their use.
By product/service type, the finished dosage form (FDF) segment held the largest revenue share of approximately 54% in the market in 2025, due to growth in the demand for tablets, capsules, syrups, etc, which increased the use of contract pharmaceutical manufacturing services. The formulation complexities and increasing demand for generic products also increased their use. Growth in outsourcing trends and regulatory expertise has also increased their use.
By drug type, the small molecules segment held a majority revenue share of approximate 62% in the market in 2025, due to their oral formulations, which increased the use of contract pharmaceutical manufacturing services, which contributed to a rise in their innovations. The growth in the demand for genetic formulation has also increased its use. This easy-handling and storage also made them ideal for contract manufacturing.
By dosage form type, the oral segment held the largest share of approximately 60% in the market in 2025, due to its easy administration, which increased its acceptance rates and promoted its contract manufacturing. The growth in chronic disease and demand for generic products also increased their manufacturing rates. Their affordable services, advanced technologies, and expertise also led to new collaborations.
North America held a dominant revenue share of approximate 40% in the contract pharmaceutical manufacturing market in 2025, due to a growth in the robust pharmaceutical industries, which increased the use of contract pharmaceutical manufacturing services. Additionally, the expansion of the outsourcing trends has also increased their use. The growth in the R&D activities, investments, and technological advancement also contributed to their increased use.
Asia Pacific is expected to grow at the fastest rate of 9.8% during the forecast period and held an approximate 30% share in the market in 2025, due to the presence of a large manufacturing base and growing demand for generics and biologics, which is increasing the use of contract pharmaceutical manufacturing services. The growing collaboration with CMOs & CDMOs and the increasing chronic disease burden are also increasing their use. Additionally, growing government initiatives and increasing outsourcing trends are also driving their demand.
